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and 40,573.33/cure, respectively. ICER was -$44,974.88/cure favoring daptomycin.
Results from the one-way sensitivity analysis showed that duration of vancomycin 
intravenous treatment, cost of hospital night stay, and duration of daptomycin intra-
venous treatment were inﬂ uential on the ICER; however, no break-even points were 
established and the model remained robust. Probabilistic sensitivity analysis displayed 
77.9% of the ICER distribution in the dominant quadrant. Acceptability curve showed 
that daptomycin was q88.6% cost-effective compared to vancomycin at all ICER
ranges. CONCLUSIONS: Daptomycin was cost-effective compared to vancomycin
due to decreased total direct cost and reduction in inpatient stay. As a result, the pro-
portion of ICER in the probabilistic sensitivity analysis favored daptomycin 77.9%
which was reﬂ ected in the acceptability curve.
PIN13
COMPARATIVE COST-EFFICACY ANALYSIS OF DARUNAVIR/R FOR 
FIRST-LINE TREATMENT OF HIV INFECTION IN THE UNITED STATES
Soorapanth S1, Brogan A1, Mrus J2, Smets E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Tibotec Therapeutics, Bridgewater, 
NJ, USA, 3Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium
OBJECTIVES: The ritonavir-boosted protease inhibitor (PI/r) darunavir (darunavir/r)
800/100 mg QD has recently been licensed in the US for use in treatment-naïve 
HIV-infected adults. The objective of this study was to compare the cost and efﬁ cacy 
of darunavir/r-based triple therapy with other combination therapies using PI/rs 
currently licensed for this patient population in the US. METHODS: Virologic efﬁ cacy 
was measured by the percentage of individuals with plasma HIV RNA  50 copies/mL 
(the current goal of antiretroviral therapy) at 48 weeks, based on a systematic review
of clinical trials of PI/r-based regimens in treatment-naïve populations. One-year 
antiretroviral therapy costs were calculated in 2008 US dollars. The base-case analysis 
considered PI/rs with a tenofovir-based backbone regimen; an abacavir-based back-
bone was considered in scenario analysis. RESULTS: The base-case analysis showed
that darunavir/r was the most efﬁ cacious PI/r, with an incremental cost-efﬁ cacy 
ratio (ICER) of $31,524 per additional individual with virologic response, when 
compared with fosamprenavir/r, the only other point on the efﬁ ciency frontier of 
PI/r-based initial therapy. All other PI/rs were less efﬁ cacious and more costly than 
darunavir/r or fosamprenavir/r, including the two most commonly prescribed: atazana-
vir/r and lopinavir/r. Before the introduction of darunavir/r, atazanavir/r was most
efﬁ cacious but with a higher ICER of $46,612 compared with fosamprenavir/r.
Darunavir/r has an average cost of $25,059 per individual with virologic response, 
compared with $25,880 and $26,526 for atazanavir/r and lopinavir/r, respectively. 
Given a ﬁ xed budget of $10 million, darunavir/r successfully treats 399 individuals,
compared with 386 and 377 for atazanavir/r and lopinavir/r, respectively. Similar
results were obtained in scenario analysis using an abacavir-based backbone. CON-
CLUSIONS: Darunavir/r 800/100 mg QD has a lower cost per individual with viro-
logic response after 48 weeks than the 2 most commonly prescribed PI/rs in 
treatment-naïve, HIV-infected adults and provides more beneﬁ t per additional cost 
than other currently available PI/rs.
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OBJECTIVES: To assess the cost-effectiveness of Truvada versus Combivir and Kivexa
in the treatment of antiretroviral naïve HIV-1 infected patients in Mexico. METHODS:
A Markov model was developed to assess the incremental cost effectiveness of Truvada
vs Combivir and Kivexa. Clinical data was derived from published clinical trials (Study 
903 and CNA30024) and other secondary sources to create a model of disease pro-
gression and treatment patterns. Both health care and treatment costs were considered.
The analysis was performed from the Mexican Health Care System perspective; costs 
were reported in 2008 US dollar. Costs and health outcomes were discounted at 5%.
A second-order probabilistic Monte Carlo sensitivity analysis was conducted to assess 
the effects of parameter uncertainty on the study ﬁ ndings. RESULTS: The model 
projects an accumulated discounted cost to the Mexican health care system per patient 
receiving the Truvada regimen of US$28,776 compared to US$24,605 for the Kivexa
regimen and US$22,999 for the Combivir regimen. The accumulated discounted effect
is 5.85 QALYs per patient receiving Truvada compared to 4.89 QALYs for Kivexa
and 4.81 QALYs for Combivir. This results in an incremental cost for Truvada and
Kivexa vs. Combivir of US$5,805 per QALY and US$ 19,436 per QALY respectively. 
Considering a willingness to pay (WTP) threshold of US$10,000 per QALY there is a
90% probability that treatment with Truvada is cost-effective relative to Combivir
CONCLUSIONS: Results from these analyses suggest that in the Mexican setting, use
of Truvada in place of standard Combivir and Kivexa for treatment of HIV is likely
to be cost effective. These conclusions are supported by conservative assumptions and
sensitivity analyses.
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OBJECTIVES: A three-dose regimen is the usual protocol for hepatitis-B vaccination. 
An alternate two-dose vaccination schedule has been recently approved for adoles-
cents. This study was conducted to compare cost-effectiveness of three- versus two-
dose hepatitis-B vaccination regimen in adolescents. METHODS: We applied health 
care provider perspectivein this study. To measure vaccination coverage and costs, we 
retrieved the data of hepatitis-B mass vaccination campaign run in 2007 covering 
1989-born adolescents in Iran. Vaccines immunogenicity were derived from literature.
The cost variables considered included recurrent costs, personnel costs, publicity costs, 
transportation costs, and overhead costs. The required data to estimate recurrent, 
national-level supervision, and publicity costs were provided from existing data and 
interview with experts. To estimate vaccine administration, provincial supervision, and
outreach costs, the data were provided from some provinces and projected to the
country. We used WHO recommended proportions to estimate transportation and 
overhead costs. RESULTS: Total cost for a three-dose campaign was estimated as $2.3
per-dose-administered. The same cost for two-dose campaign would be $2.1 per-dose-
administered. Total cost of a three-dose campaign, in the best scenario was $7.1 per-
person-seroprotected and would be $5.5-$9.4 in alternative scenarios according to 
sensitivity analysis. The same cost for a two-dose campaign, in the best scenario was
$4.5 per-person-seroprotected and would be $3.6-$8.7 in alternative scenarios. To 
immunize one more person in a 3-dose protocol compared to a 2-dose protocol, $58.6 
would be spent by health system. This cost would be $9.6-$155.3 in various scenarios. 
In addition, in some scenarios two-dose protocol might have deﬁ nite priority to three-
dose protocol because of both higher effectiveness and lower cost. CONCLUSIONS:
Running a two-dose protocol HBV vaccination campaign in adolescents instead of 
current three-dose protocol campaign is more cost-effective. Conducting an analysis 
with societal perspective which includes vaccinee costs, two-dose protocol will be more 
advantageous.
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OBJECTIVES: This study aims to conduct cost-effectiveness analysis of posaconazole 
(POS) compared with standard azole therapy including ﬂ uconazole (FLU) or itracon-
azole (ITR) for prophylaxis of invasive fungal infection (IFI) with netropenia in South 
Korea. METHODS: A decision tree was used to estimate the proportion of the surviv-
ing patients cohort during the 100-day period following initiation of prophylaxis. The
surviving patients in the decision tree were extrapolated to a lifetime horizon using
Markov model to estimate the incremental cost per life-year gained. Effectiveness 
parameters used in the decision tree were obtained from clinical trial. And IFI treat-
ment costs were estimated from hospital survey. The price of POS was proposed by 
the manufacturing company and calculated based on the average KRW-Euro exchange
rate of 2008. Deterministic one-way and probabilistic sensitivity analyses (PSA) were 
conducted, as well. RESULTS: Base-case analysis showed that POS resulted in a gain
of 0.092 life years (2.417 vs. 2.324) with KRW 1,457,512 of additional costs (KRW 
5,827,956 vs. 4,370,443) per patient relative to FLU or ITR. While the drug cost of 
POS was higher than that of FLU/ITR, expected IFI treatment costs were lower in
patients with POS than in patients with FLU/ITR. The incremental cost-effectiveness 
ratio was KRW 15,798,087 (€9,995) per life-year gained. PSA revealed that POS was 
cost-effective with a 50% probability at about KRW 22,000,000 (€14,000). CON-
CLUSIONS: The results of cost-effectiveness analysis showed that POS is potentially 
beneﬁ cial in IFI prophylaxis among patients with neutropenia in South Korea.
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BACKGROUND: Human papillomavirus (HPV), a precursor for cervical cancer, is 
the most common sexually transmitted infection in the United States. A quadrivalent 
vaccine (Gardasil), which was approved by the US FDA in June 2006, targets HPV 
16 and 18, which cause 70% cervical cancer, and HPV 6 and 11, which cause genital 
warts. OBJECTIVES: To evaluate the cost-effectiveness of HPV vaccine compared to 
the current screening program. The result expressed by quality-adjusted life-years
(QALYs), and incremental cost-effectiveness ratios (ICER). METHODS: A backward 
induction model was used to estimate the results. A cohort of female aged 12 to 70 
was projected. Girls are vaccinated at age 12, assuming that this vaccine is life-long 
protective, 85% efﬁ cacy, women complete 3 shots and assuming a 3% discount rate.
Model parameters were taken from published literature. Costs and QALYs were cal-
culated in 5-years intervals. One-way sensitivity analyses were conducted on critical 
or uncertain model parameters. RESULTS: HPV vaccines had both higher total costs 
($48,342) and higher QALYs (3.07 days) than girls receiving screening tests. The 
vaccine cost-effectiveness ratio was $15,749 per quality-adjusted life-year (QALY) 
